Is DaVita (DVA) Stock Undervalued Right Now?
Werte in diesem Artikel
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.One company to watch right now is DaVita (DVA). DVA is currently sporting a Zacks Rank of #1 (Strong Buy) and an A for Value. The stock has a Forward P/E ratio of 14.52. This compares to its industry's average Forward P/E of 20.35. Over the last 12 months, DVA's Forward P/E has been as high as 15.41 and as low as 12.18, with a median of 14.05.DVA is also sporting a PEG ratio of 0.80. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DVA's industry has an average PEG of 2.12 right now. Over the past 52 weeks, DVA's PEG has been as high as 1.26 and as low as 0.71, with a median of 0.85.Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a prefered metric because revenue can't really be manipulated, so sales are often a truer performance indicator. DVA has a P/S ratio of 1.08. This compares to its industry's average P/S of 1.39.Finally, we should also recognize that DVA has a P/CF ratio of 8.99. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. DVA's P/CF compares to its industry's average P/CF of 25.02. Within the past 12 months, DVA's P/CF has been as high as 9.16 and as low as 6.71, with a median of 8.20.These are just a handful of the figures considered in DaVita's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that DVA is an impressive value stock right now.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Ausgewählte Hebelprodukte auf DaVita HealthCare Partners
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DaVita HealthCare Partners
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu DaVita HealthCare Partners Inc
Analysen zu DaVita HealthCare Partners Inc
Datum | Rating | Analyst | |
---|---|---|---|
03.01.2019 | DaVita HealthCare Partners Buy | Deutsche Bank AG | |
14.12.2018 | DaVita HealthCare Partners Overweight | Barclays Capital | |
12.12.2017 | DaVita HealthCare Partners Outperform | Robert W. Baird & Co. Incorporated | |
08.11.2017 | DaVita HealthCare Partners Sector Perform | RBC Capital Markets | |
13.12.2016 | DaVita HealthCare Partners Neutral | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
03.01.2019 | DaVita HealthCare Partners Buy | Deutsche Bank AG | |
14.12.2018 | DaVita HealthCare Partners Overweight | Barclays Capital | |
12.12.2017 | DaVita HealthCare Partners Outperform | Robert W. Baird & Co. Incorporated | |
27.04.2015 | DaVita HealthCare Partners Outperform | Robert W. Baird & Co. Incorporated | |
18.10.2011 | DaVita outperform | Robert W. Baird & Co. Incorporated |
Datum | Rating | Analyst | |
---|---|---|---|
08.11.2017 | DaVita HealthCare Partners Sector Perform | RBC Capital Markets | |
13.12.2016 | DaVita HealthCare Partners Neutral | Robert W. Baird & Co. Incorporated | |
04.11.2015 | DaVita HealthCare Partners Sector Perform | RBC Capital Markets | |
06.08.2015 | DaVita HealthCare Partners Sector Perform | RBC Capital Markets | |
13.03.2015 | DaVita HealthCare Partners Hold | Deutsche Bank AG |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DaVita HealthCare Partners Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen